Immutep Ltd has released a press release.
Webcast slides for 1st line NSCLC data from TACTI-002 trial
Filed with ASX ·
6ix hasn’t read this filing yet.
In the deck
Story so far
Earlier from Immutep
- Immutep announces publication of ASCO 2022 abstracts
- New & significant data from AIPAC phase 2b trial in MBC
- Immutep to announce new TACTI-002 data at ASCO 2022
- Efti with Keytruda shows encouraging activity in lung cancer
- Immutep announces publication of ELCC 2022 abstract
Later from Immutep
- Immutep granted Japanese Patent for IMP761
- Quarterly Activities/Appendix 4C Cash Flow Report
- TACTI-002 2nd line lung cancer data presented at 2022 WCLC
- Japanese Patent Grant for efti, soluble LAG-3 with anti-PD-1
- Appendix 4E & 2022 Full Year Statutory Accounts
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep